Income Taxes (Details Narrative) - USD ($)	Jul. 31, 2017	Jul. 31, 2016
Pretax losses arising from domestic operations	$ (76,823,599)	$ (1,374,725)
Pretax losses arising from foreign operations	(869,116)	$ (504,101)
Generex Biotechnology Corporation
NOL carryforwards, expiring through 2036	200,000,000
Generex Pharmaceuticals, Inc
NOL carryforwards, expiring through 2036	34,700,000
Antigen Express, Inc
NOL carryforwards, expiring through 2036	$ 31,300,000

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=96869850&loc=d3e28680-109314

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Name:	us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant